Onyx Biotec
: ONYX · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Onyx Biotec's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Onyx Biotec Ltd is a pharmaceutical company specialising in the manufacture of sterile water for injections, dry powder injections, and dry syrups. The company operates primarily as a contract manufacturer, providing end-to-end product development and regulatory dossier filing services for domestic and international clients.
Business Model
The company operates on a B2B model, acting as a contract manufacturer for major pharmaceutical corporations. It generates revenue through the production of sterile pharmaceutical products and the provision of technical services, including regulatory support.
- Business Model:B2B Contract Manufacturing
Growth Outlook
Growth is expected to be driven by the expansion of contract manufacturing services and the continued demand for sterile pharmaceutical products in both Indian and global markets.
Key Risks
- Regulatory Compliance. Failure to adhere to stringent international and domestic quality standards for sterile products could lead to product recalls or loss of manufacturing licences.
- Client Concentration. As a B2B contract manufacturer, the company may be vulnerable to the loss of key corporate clients or shifts in their outsourcing strategies.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can significantly impact manufacturing margins.
- Competitive Pressure. The pharmaceutical contract manufacturing sector is highly fragmented, leading to intense price competition from other domestic and international players.
Start your research today
Unlock AI insights, financials, peers and live data on Onyx Biotec and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Onyx BiotecONYX | ₹76 Cr | — | — | — | 4.9% | — | — | -12.4% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Onyx Biotec
: ONYX · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Onyx Biotec's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Onyx Biotec Ltd is a pharmaceutical company specialising in the manufacture of sterile water for injections, dry powder injections, and dry syrups. The company operates primarily as a contract manufacturer, providing end-to-end product development and regulatory dossier filing services for domestic and international clients.
Business Model
The company operates on a B2B model, acting as a contract manufacturer for major pharmaceutical corporations. It generates revenue through the production of sterile pharmaceutical products and the provision of technical services, including regulatory support.
- Business Model:B2B Contract Manufacturing
Growth Outlook
Growth is expected to be driven by the expansion of contract manufacturing services and the continued demand for sterile pharmaceutical products in both Indian and global markets.
Key Risks
- Regulatory Compliance. Failure to adhere to stringent international and domestic quality standards for sterile products could lead to product recalls or loss of manufacturing licences.
- Client Concentration. As a B2B contract manufacturer, the company may be vulnerable to the loss of key corporate clients or shifts in their outsourcing strategies.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can significantly impact manufacturing margins.
- Competitive Pressure. The pharmaceutical contract manufacturing sector is highly fragmented, leading to intense price competition from other domestic and international players.
Start your research today
Unlock AI insights, financials, peers and live data on Onyx Biotec and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026